First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

被引:18
作者
Sun, Huikai [1 ]
Monenschein, Holger [1 ]
Schiffer, Hans H. [1 ]
Reichard, Holly A. [1 ]
Kikuchi, Shota [1 ]
Hopkins, Maria [1 ]
Macklin, Todd K. [1 ]
Hitchcock, Stephen [1 ]
Adams, Mark [1 ]
Green, Jason [1 ]
Brown, Jason [1 ]
Murphy, Sean T. [1 ]
Kaushal, Nidhi [1 ]
Collia, Deanna R. [1 ]
Moore, Steve [1 ]
Ray, William J. [1 ]
English, Nicole Marion [1 ]
Carlton, Mark Beresford Lewis [2 ]
Brice, Nicola L. [2 ]
机构
[1] Takeda Calif, San Diego, CA 92121 USA
[2] Cerevance Ltd, Cambridge, England
关键词
RECEPTOR; INHIBITION; MECHANISMS; DOPAMINE; LEVODOPA; LIGAND; NEURON; MOUSE;
D O I
10.1021/acs.jmedchem.0c02081
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Parkinson's disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled receptor (GPCR) with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSNs) of the indirect pathway, a striatal brain circuit which shows aberrant hyperactivity in PD patients. Potent and selective GPR6 inverse agonists (IAG) were developed starting from a low-potency screening hit (EC50 = 43 mu M). Herein, we describe the multiple parameter optimization that led to the discovery of multiple nanomolar potent and selective GPR6 IAG, including our clinical compound CVN424. GPR6 IAG reversed haloperidol-induced catalepsy in rats and restored mobility in the bilateral 6-OHDA-lesioned rat PD model demonstrating that inhibition of GPR6 activity in vivo normalizes activity in basal ganglia circuitry and motor behavior. CVN424 is currently in clinical development to treat motor symptoms in Parkinson's disease.
引用
收藏
页码:9875 / 9890
页数:16
相关论文
共 38 条
[1]   Orphan G protein-coupled receptors: The role in CNS disorders [J].
Alavi, Mohaddeseh Sadat ;
Shamsizadeh, Ali ;
Azhdari-Zarmehri, Hassan ;
Roohbakhsh, Ali .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 98 :222-232
[2]   Dopamine receptors - IUPHAR Review 13 [J].
Beaulieu, Jean-Martin ;
Espinoza, Stefano ;
Gainetdinov, Raul R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (01) :1-23
[3]   Dopamine receptor agonists for Parkinson's disease [J].
Blandini, Fabio ;
Armentero, Marie-Therese .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (03) :387-410
[4]  
Brice Nicola L, 2021, J Pharmacol Exp Ther, V377, P407, DOI 10.1124/jpet.120.000438
[5]   Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications [J].
Cenci, M. Angela .
FRONTIERS IN NEUROLOGY, 2014, 5
[6]   Pharmacological Treatment of Parkinson Disease A Review [J].
Connolly, Barbara S. ;
Lang, Anthony E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16) :1670-1683
[7]   PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS [J].
Dahlin, Jayme L. ;
Nissink, J. Willem M. ;
Strasser, Jessica M. ;
Francis, Subhashree ;
Higgins, LeeAnn ;
Zhou, Hui ;
Zhang, Zhiguo ;
Walters, Michael A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) :2091-2113
[8]   Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits [J].
Deuschl, Guenther ;
Agid, Yves .
LANCET NEUROLOGY, 2013, 12 (10) :1025-1034
[9]  
Dickson DW, 2009, LANCET NEUROL, V8, P1150, DOI 10.1016/S1474-4422(09)70238-8
[10]   Application of a Translational Profiling Approach for the Comparative Analysis of CNS Cell Types [J].
Doyle, Joseph P. ;
Dougherty, Joseph D. ;
Heiman, Myriam ;
Schmidt, Eric F. ;
Stevens, Tanya R. ;
Ma, Guojun ;
Bupp, Sujata ;
Shrestha, Prerana ;
Shah, Rajiv D. ;
Doughty, Martin L. ;
Gong, Shiaoching ;
Greengard, Paul ;
Heintz, Nathaniel .
CELL, 2008, 135 (04) :749-762